Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma
| Autor: | Khê Hoang-Xuan, Jean-Yves Delattre, László Sipos, Martin J.B. Taphoorn, Hans J.J.A. Bernsen, Denis Lacombe, Marc Frenay, Alba A. Brandes, Thierry Gorlia, Martin J. van den Bent, Charles J. Vecht, Roelien H. Enting, Johan M. Kros, Cees C. Tijssen, Pim J. French, Mathilde C.M. Kouwenhoven, Winand N.M. Dinjens, Anouk Allgeier, Wolfgang Grisold |
|---|---|
| Přispěvatelé: | Neurology, CCA - Innovative therapy, Pathology, Faculteit Medische Wetenschappen/UMCG |
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Vincristine Pathology medicine.medical_treatment Oligodendroglioma Brain tumor IDH2 MUTATIONS Kaplan-Meier Estimate Procarbazine PHENOTYPE Disease-Free Survival EUROPEAN ORGANIZATION Lomustine Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine Oligodendroglial Tumor RECURRENT 1P/19Q LOSS In Situ Hybridization Fluorescence Chemotherapy Temozolomide Brain Neoplasms business.industry TEMOZOLOMIDE PHASE-III TRIAL medicine.disease GRADE GLIOMA GROUP TRIAL 9402 Chemotherapy Adjuvant business Gene Deletion Follow-Up Studies medicine.drug RADIOTHERAPY |
| Zdroj: | Journal of Clinical Oncology, 31(3), 344-350. American Society of Clinical Oncology van den Bent, M J, Brandes, A A, Taphoorn, M J B, Kros, J M, Kouwenhoven, M C M, Delattre, J Y, Bernsen, H J J A, Frenay, M, Tijssen, C C, Grisold, W, Sipos, L, Enting, R H, French, P J, Dinjens, W N M, Vecht, C J, Allgeier, A, Lacombe, D, Gorlia, T & Hoang-Xuan, K 2013, ' Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951 ', Journal of Clinical Oncology, vol. 31, no. 3, pp. 344-350 . https://doi.org/10.1200/JCO.2012.43.2229 Journal of Clinical Oncology, 31(3), 344-350. AMER SOC CLINICAL ONCOLOGY |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/JCO.2012.43.2229 |
| Popis: | Purpose Anaplastic oligodendroglioma are chemotherapy-sensitive tumors. We now present the long-term follow-up findings of a randomized phase III study on the addition of six cycles of procarbazine, lomustine, and vincristine (PCV) chemotherapy to radiotherapy (RT). Patients and Methods Adult patients with newly diagnosed anaplastic oligodendroglial tumors were randomly assigned to either 59.4 Gy of RT or the same RT followed by six cycles of adjuvant PCV. An exploratory analysis of the correlation between 1p/19q status and survival was part of the study. Retrospectively, the methylation status of the methyl-guanine methyl transferase gene promoter and the mutational status of the isocitrate dehydrogenase (IDH) gene were determined. The primary end points were overall survival (OS) and progression-free survival based on intent-to-treat analysis. Results A total of 368 patients were enrolled. With a median follow-up of 140 months, OS in the RT/PCV arm was significantly longer (42.3 v 30.6 months in the RT arm, hazard ratio [HR], 0.75; 95% CI, 0.60 to 0.95). In the 80 patients with a 1p/19q codeletion, OS was increased, with a trend toward more benefit from adjuvant PCV (OS not reached in the RT/PCV group v 112 months in the RT group; HR, 0.56; 95% CI, 0.31 to 1.03). IDH mutational status was also of prognostic significance. Conclusion The addition of six cycles of PCV after 59.4 Gy of RT increases both OS and PFS in anaplastic oligodendroglial tumors. 1p/19q-codeleted tumors derive more benefit from adjuvant PCV compared with non–1p/19q-deleted tumors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|